Agenus (NASDAQ:AGEN) reported its financial results for the fourth quarter and full year ended December 31, 2025, marking a transition from a purely clinical-stage company to one generating initial pre-commercial revenue.
CytomX Therapeutics (NASDAQ:CTMX) reported its full-year 2025 financial results and a strategic business update on March 16, 2026, highlighting the continued evolution of its Probody® platform.
WW International (NASDAQ:WW) reported its fourth-quarter and full-year 2025 results on March 16, 2026, signaling a successful stabilization of its business model following a major financial restructuring mid-year.
Eli Lilly and Company (NYSE:LLY) on Monday announced positive topline results from the Phase 3 ADorable-1 trial evaluating EBGLYSS (lebrikizumab-lbkz) in patients aged six months to 18 years with moderate-to-severe atopic dermatitis.
Alto Neuroscience (NYSE:ANRO) reported its full-year 2025 financial results, highlighting a strengthened balance sheet and a disciplined approach to research and development.
Immutep (NASDAQ:IMMP) announced on March 13, 2026, that it will shut down its Phase III TACTI-004 clinical trial evaluating eftilagimod alpha ("efti") in combination with anti-PD-1 therapy for first-line non-small cell lung cancer (NSCLC).
Barinthus Biotherapeutics (NASDAQ:BRNS) has entered into a proposed all-stock business combination with Clywedog, a strategic move aimed at consolidating resources and advancing a diversified immunotherapy pipeline.
Purple Biotech (NASDAQ:PPBT) posted a net loss of $26.4 million for the full year 2025, a result heavily impacted by a $20.5 million non-cash impairment of its CM24 and NT219 programs.
Xenetic Biosciences (NASDAQ:XBIO) reported a 19% increase in royalty revenue for the full year 2025, providing a financial cushion as the company moves closer to human clinical trials for its lead immuno-oncology program.
bioAffinity Technologies (NASDAQ:BIAF) reported fiscal year 2025 results that underscore an aggressive transition from a broad laboratory service model to a specialized, high-growth diagnostic powerhouse focused on early-stage lung cancer detection.
Savara (NASDAQ:SVRA) provided a year-end financial update that underscores the company’s transition toward the commercial stage, with increased spending on pre-launch activities for its lead drug candidate, molgramostim.
Acurx Pharmaceuticals (NASDAQ:ACXP) on Friday reported a full-year 2025 net loss of $8 million, with cash and cash equivalents of $7.6 million as of December 31, 2025, supported by approximately $4 million in gross proceeds from its equity line of credit during the year.
